Korean AI startups Allganize, Neurophet raise over $35 mn (The Korea Economic Daily):
Founded in 2016, the company plans to next year roll out its new AI analysis program that can detect side effects of Alzheimer’s disease treatments with a microhemorrhage diagnosis.
The Korean AI startup is famous for its flagship AI analysis technologies, Neurophet AQUA, which is a brain MRI analysis technology, and Neurophet SCALE PET, an AI-based positron emission tomography (PET) image analysis program.
It plans to go public in Korea next year, said Neurophet CEO Bin Joon-gil, adding that it is currently working with its underwriter Mirae Asset Securities for the IPO.
Neurophet secures 20 billion in Series C funding to launch AI dementia treatment solution (Korea Biomedical Review):
Alzheimer’s drugs such as lecanemab and donanemab, being developed and launched by global pharmaceutical companies, are anti-amyloid antibody treatments that aim to remove amyloid beta … Amyloid-PET imaging is required before prescribing treatment to determine whether amyloid beta is deposited in the cerebral cortex and whether it decreases afterward.
Neurophet has developed Neurophet SCALE PET, a software that automatically analyzes amyloid-PET images that would otherwise require a time-consuming manual analysis by radiologists.
Neurophet SCALE PET combines PET and MRI images to analyze Alzheimer’s disease biomarkers such as amyloid beta protein and tau protein at ultra-high speed.
Anti-amyloid antibody therapies, on the other hand, have the side effect of causing Amyloid-Related Imaging Abnormalities (ARIA), which are swelling and microhemorrhages in the brain during administration.
Neurophet said it has advanced technology in the field of automated quantification of vascular neuropathology that can monitor and analyze ARIA and plans to launch an Alzheimer’s total solution including ARIA analysis technology next year.